Immunotherapy in Combination with Chemotherapy for Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks estrogen and progesterone receptors and does not overexpress the human epidermal growth factor receptor 2 (HER2). Previous treatment options for TNBC were limited to chemotherapy alone, resulting in a poor pati...

Deskribapen osoa

Gorde:

Xehetasun bibliografikoak
Beste egile batzuk:	Meléndez-Solano, Elizabeth, Chapa, Christian, Stevens Barrón, Jazmín Cristina
Formatua:	Artículo
Hizkuntza:	en_US
Argitaratua:	2023
Gaiak:	Cancer breast triple negative breast cancer immunotherapy efficacy safety atezolizumab camrelizumab paclitaxel gemcitabine info:eu-repo/classification/cti/2 info:eu-repo/classification/cti/3
Sarrera elektronikoa:	https://doi.org/10.2174/1389557523666230517152538 https://pubmed.ncbi.nlm.nih.gov/37198990/
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Izan zaitez lehena ohar bat uzten!

Immunotherapy in Combination with Chemotherapy for Triple-Negative Breast Cancer

Antzeko izenburuak